The recent appearance of Staphylococcus aureus and Staphylococcus epidermidis strains that have reduced susceptibility to vancomycin, and the spread of vancomycin-resistant enterococci, raise the specter of endovascular infections that will be difficult or impossible to cure with available drugs. We review issues concerning the prophylactic use of vancomycin in adult cardiology and cardiac surgery with special attention to dosing and indications. There is no indication for the routine use of prophylactic vancomycin in pacemaker implantations, cardiac catheterization, and transesophageal echocardiography. In institutions with a high incidence of methicillin-resistant S. aureus and S. epidermidis, vancomycin may be used for antibiotic prophylaxis in place of cephalosporins for pacemaker or defibrillator implantation. The strongest evidence in support of the prophylactic use of vancomycin is during cardiac surgeries, particularly valvular surgeries in institutions with a high prevalence of methicillin-resistant S. aureus and S. epidermidis. When vancomycin is used prior to open heart surgery, the dose should be 15 mg/kg rather than the standard 1 g dose that is often recommended in the literature and used by 85% of institutional pharmacists who responded to our survey. Cardiologists and cardiac surgeons should assume leadership roles in promoting its responsible use.
Vancomycin is the mainstay of therapy against staphylococci resistant to the ,-lactam antibiotics-the socalled methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE). The current high prevalence of MRSA and MRSE at most hospitals makes vancomycin an indispensable drug in adult cardiology and cardiac surgery. Recent reports of S. aureus and coagulase-negative staphylococcal strains that have reduced susceptibility to vancomycin raise the possibility that we may soon face Overview ofVancomycin Pharmacology Vancomycin was the first glycopeptide antibiotic and is the only drug in this class currently available in the United States. Newer glycopeptide antibiotics being studied include teicoplanin, daptomycin, and ramoplanin; as yet, none of these seems clearly superior to vancomycin. Vancomycin inhibits the synthesis of peptidoglycan polymers in the bacterial cell wall and is bactericidal only against multiplying organisms. Although vancomycin exerts its main effect by mimicking the D-alanyl-D-alanine precursor of peptidoglycan, multiple mechanisms of action help account for the low frequency with which resistance emerges (9, 10) .
Spectrum of Activity
Vancomycin is active against nearly all gram-positive bacteria, except for the newly emerging vancomycinresistant enterococci (2) . Intrinsic resistance has been encountered in only a few species, such as Erysipelothrix, Pediococcus, Leuconostoc, Lactobacillus, and three enterococci seldom implicated in human disease: Enterococcus gallinarum, E. casseliflavus, and E. flavescens (11) . Vancomycin has no activity against most gram-negative bacteria, although a few species such as Flavobacterium meningosepticum, Neisseria meningitides, and Neisseria gonorrhoeae are susceptible to high concentrations.
Many physicians have the impression that vancomycin is the most potent available antistaphylococcal antibiotic. Actually, the antistaphylococcal penicillins such as oxacillin and nafcillin surpass vancomycin for treatment of infections caused by mutually susceptible strains of S. aureus. The inferior antistaphylococcal activity of vancomycin presumably explains why the mortality rate is higher with MRSA bacteremia than with bacteremia caused by methicillin-susceptible S. aureus strains (12) . Some staphylococcal strains are relatively tolerant to the bactericidal action of vancomycin, a phenomenon manifested in vitro by minimum bactericidal concentration values that are significantly higher than the minimum inhibitory concentration (MIC) values (13) . This observation may explain why vancomycin sometimes fails to cure staphylococcal endocarditis in injection drug users, a setting in which oxacillin or nafcillin nearly always succeed (14, 15) . However, one study in a guinea pig model showed that vancomycin prophylaxis was superior to cefazolin in the prevention of intramuscular infection by both methicillin-susceptible and methicillin-resistant S. aureus (16) .
Toxicity
The unwanted effects of vancomycin include ototoxicity, enhancement of the nephrotoxicity of other drugs (eg, aminoglycoside antibiotics), neutropenia, fixeddrug eruptions, and phlebitis. Of more concern to prophylactic use is the "red man syndrome," variably characterized by flushing of the upper body, hypotension, itching, and-less often-chest pain and muscle spasm. Cardiac arrest has been reported (17, 18) . These effects are attributed to the nonimmunologic release of histamine from mast cells, correlated with the rate of vancomycin infusion (19) . Bolus infusions are especially dangerous. Recognition of the relationship between the red man syndrome and rapid infusion (< 30 minutes) led to the practice of slow vancomycin infusion (> 1 hour). Pretreatment of patients with an antihistamine such as diphenhydramine or hydroxyzine prior to the first dose of vancomycin protects against red man syndrome (20, 21) . Less common anaphylactoid reactions to vancomycin include oliguria, generalized edema, and noncardiogenic pulmonary edema (22) .
Various investigators have studied the hemodynamic effects of vancomycin during cardiovascular surgery. One group observed that 25% of 116 consecutive patients developed hypotension, which was severe in one-half of the patients (23) . A second group determined that although initial doses of vancomycin were well tolerated, subsequent doses caused hypotension that often required a norepinephrine infusion after bypass (24) . A third group concluded that starting the infusion after initiating bypass could minimize the adverse reactions to vancomycin (25) . A fourth group found that vancomycin given over 1 hour prior to bypass did not suppress cardiac function, even though vancomycin depresses cardiac function by about 15% in animal studies (26) . Indeed, because the significance of this controversial adverse hemodynamic affect of vancomycin remains unclear, a slower infusion rate and the administration of intravenous fluid in response to hypotension may reduce the incidence and severity of this adverse reaction.
Dosing
Farber et al noted two cases of early-onset prosthetic valve endocarditis that was due to S. epidermidis in patients who were given preoperative vancomycin at a dosage of 500 mg (7.5 mg/kg) every 6 hours (27) . Since serum concentrations of 6.3 p//mL are required for the effective killing of S. epidermidis organisms in patients with prosthetic valve endocarditis, the authors had concerns regarding low serum levels with the tra-ditional 1-g preoperative dose. On the basis of observation, they gave 15 mg/kg of vancomycin to 10 patients with a history of penicillin allergy who were undergoing cardiopulmonary bypass and observed serum levels of 7.0 ± 3.0 ,ug/mL during surgery. Therefore, they recommended an initial dose of 15 mg/kg just prior to surgery, followed by a second dose of 10 mg/kg after the termination of bypass (27) . We gave vancomycin to 12 patients according to this protocol and observed serum levels similar to those obtained by Farber et al (Bryan CS, Morgan SL, Smith CW, unpublished observations). The use of a standard 1 -g dose will result in overmedication of small patients and undermedication of large patients (27, 28) . However, some authorities recommend a l-g dose for all patients (29) . To gain better insight into the commonly used dose of vancomycin for prophylaxis, we sent a brief questionnaire to hospital pharmacists at 50 institutions throughout the United States that asked the dose of vancomycin they generally used. Of 39 respondents, 33 (85%) gave the usual dose as 1 g; one as 500 mg; and five as 15 mg/kg. Two randomized trials compared the use of different doses of vancomycin vs cephalosporins for prophylaxis in cardiac surgery (30, 31) . These studies concluded that using 15 mg/kg of vancomycin resulted in a significant reduction of wound infections compared with cephalosporin. However, it should be mentioned that the Maki et al study did not differentiate between the procedural mix, as it included various major vascular as well as cardiac surgeries. Nevertheless, an initial preoperative dose of 15 mg/kg is suggested rather than a standard 1 -g dose. In addition, this regimen has been shown to maintain adequate therapeutic vancomycin levels during prolonged cardiac surgery for up to 8 hours (32, 33) . In a related study of vancomycin prophylaxis for coronary artery bypass grafting, Vuorisalo et al found therapeutic serum levels up to 8 hours from the time a single 1.5-g dose was administered (34) .
The previous recommendation was that the adipose tissue of obese patients be taken into account when dosing vancomycin (35) . However, dosing that is based on ideal body weight can result in suboptimal peak and trough levels in obese patients. The recommendation now is that obese patients, including the morbidly obese, should be dosed on a weight basis with the admonition that trough drug levels (and perhaps peak levels) should be measured if therapy is to be prolonged (36, 37) . In most situations, however, the common practice of measuring peak and trough serum levels during therapy is of questionable value (29, (38) (39) (40) .
The duration of antimicrobial prophylaxis for most procedures is controversial. However, most experts recommend one preoperative dose administered within 60 minutes before the procedure and, at most, one or two postoperative doses (41, 42) .
Indications and Efficacy
Cefazolin, cefamandole, and cefuroxime are the most commonly recommended drugs for prophylaxis against staphylococcal infection in surgery. Vancomycin is reserved for patients with histories of penicillin allergy or for settings in which methicillinresistant staphylococci frequently cause wound infections (29) . An animal study revealed that vancomycin was superior to cefazolin in preventing infection by methicillin-susceptible and methicillin-resistant strains of S. aureus in a guinea pig model of intramuscular wound infection (16) . In the rat and rabbit models of experimental S. epidermidis endocarditis, vancomycin compared favorably with cefamandole and cefazolin (43, 44) . Penetration of vancomycin into cardiac tissues and sternal bone appears to be adequate in most-but not all-patients (45, 46) .
Prosthetic Valve Surgery
Coagulase-negative staphylococci are the most common bacteria that cause endocarditis within 12 months of valve replacement, and it is thought that these bacteria are usually inoculated onto the sewing ring during surgery (47) . The high prevalence of MRSE at most institutions makes vancomycin an attractive antibiotic for prevention of these infections. Antunes et al reported that a change from a cephalosporinbased protocol to a two-drug regimen of vancomycin plus an aminoglycoside (netilmicin) dramatically reduced the rate of prosthetic valve endocarditis at their institution in Portugal (48) .
The optimum duration of prophylactic antibiotic therapy for prosthetic valve replacement is unknown. Most authorities recommend that therapy be limited to 2 days, which is supported by at least one comparative study (49) . Some surgeons prefer to continue therapy for a longer duration for hemodynamically unstable patients who require the continued presence of central venous and arterial pressure monitoring catheters. This is in attempt to prevent seeding of the prostheses during the course of transient catheter-associated bacteremia. However, no data supports prolonged antibiotic prophylaxis beyond 24 to 48 hours. Niederhauser et al found that prolonged low-dose vancomycin after cardiac surgery did not reduce the rate of colonization or infections of intravascular catheters with gram-positive bacteria (50) .
OtherTypes of Cardiac Surgery
Substantial evidence indicates that a short course of perioperative antibiotic therapy reduces the incidence of infections related to cardiopulmonary bypass graft surgery. Cephalosporins are the most commonly used antibiotics for this purpose (51) (52) (53) . Maki et al gave vancomycin, cefazolin, or cefamandole to 321 adult patients who were undergoing cardiac or major vascular procedures. Wound infection rates were 3.7% after vancomycin, 11.5% after cefazolin, and 12.3% after cefamandole (P < .05); and no chest wound infections occurred in the patients who were given vancomycin (30) . In this study, the vancomycin dose was 15 mg/kg or 1 g, or whichever was greater.
Danish investigators found vancomycin to be superior to penicillin G for the prevention of postoperative infections in open heart surgery (54) . On the other hand, Vuorisalo et al observed no difference in the rate of surgical-site infections among 444 patients who received cefuroxime (3.2%) and 440 patients who received vancomycin (3.5%) (55). Finkelstein et al and Salminen et al made similar observations when they compared the efficacy of cefazolin and ceftriaxone, respectively, with vancomycin, although those studies did not use the recommended dose of 15 mg/kg of vancomycin (31, 56) . Also, Pear et al observed that voluntary reduction of vancomycin use in favor of a cephalosporin had no effect on the rate of postoperative infections after coronary artery bypass graft surgery (57) .
On balance, the issue of whether vancomycin or a cephalosporin should be used as a first-line agent is unresolved (58) . Consultants to The Medical Letter recommended cefazolin, cefuroxime, or vancomycin as drugs of choice for prophylaxis during cardiac surgery of all types, with a note that vancomycin should be considered not only for patients with allergy to penicillins and cephalosporins, but also in hospital settings where MRSA and MRSE often cause wound infections (59) . As already noted, MRSA and MRSE are now prevalent at most major teaching institutions in the United States.
Permanent Cardiac Pacemaker Implantation
Infection complicates 0.13% to 19.9% of permanent cardiac pacemaker implantations (60) . Endocarditis sometimes occurs and usually requires the removal of the entire endocardial system, followed by 6 weeks of appropriate antibiotic therapy (61) . Staphylococci are the most frequent isolates, but in contrast to prosthetic valve endocarditis, most cases of early-onset endocarditis after pacemaker implantation are due to S. aureus. This was the case with 88% of staphylococcal isolates that caused pacemaker endocarditis in one large series (62) .
Historically, it was believed that prophylactic antibiotics do not reduce the overall infection rate. However, two cases of severe S. aureus bacteremia lead Hartstein et al to conclude that antibiotics might reduce the severity of infection (63, 64) . More recently, four of five placebo-controlled trials and one metaanalysis indicated that prophylactic antibiotic therapy reduces the incidence of infections related to pacemaker implantation (65) (66) (67) (68) (69) (70) . On the basis of controlled trials and various observational studies, it seems that prophylactic antibiotics are widely used prior to permanent pacemaker implantation and also that definitive guidelines are needed since little or no standardization exists. The literature does not support the use of vancomycin as the first-line prophylaxis agent for the placement of a permanent pacemaker.
Cardiac Defibrillator Implantation
Use of prophylaxis for placement of implantable cardioverter defibrillators is a common practice (71) . We are aware of no comparative trials of vancomycin for this indication. Because implantable cardioverter defibrillators are implanted percutaneously, similar to pacemakers, prophylactic antibiotic use should therefore follow the same guidelines.
Cardiac Catheterization. Bacteremia is rare after diagnostic cardiac catheterization and also after percutaneous transluminal coronary angioplasty (72) (73) . Groin infection, septic endarteritis, and cardiac abscess have been reported after early groin repuncture; in the presence of already indwelling vascular access, or when a delay occurs in the removal of the arterial sheath after the procedure is completed (74) (75) (76) (77) . Although there are no standard recommendations, prophylactic antibiotic therapy might be considered in this setting. We are aware of no data pertaining to the use of vancomycin for cardiac catheterization and percutaneous intervention prophylaxis.
Transesophageal Echocardiography
Numerous studies show that no significant bacteremia is associated with transesophageal echocardiography, even in high-risk patients. Therefore, antibiotic prophylaxis is not recommended for this procedure (78-82).
Discussion of Current Issues
When and how should vancomycin be used prophylactically? Prophylactic use of vancomycin should be consistent with the HICPAC guidelines and kept brief ( Table 1) . Its use is, in fact, encouraged in institutions where there is high prevalence of MRSA and MRSE as determined by the institution's infection control department. A recently published consensus panel defines high rates of MRSA transmission as greater than 0.5 new nosocomial cases of MRSA per 100 admissions for hospitals with at least 500 beds (84) . Brief courses (24 to 48 hours) reduce the environmental pressure that promotes the development of vancomycin-resistant microorganisms and also lower the risk of superinfections caused by other bacteria and yeasts.
Should vancomycin be used more widely for prophylaxis? Conventional wisdom holds that cardiologists and cardiac surgeons should be discouraged from the frequent use of vancomycin as a prophylactic agent, since wide use of vancomycin promotes the emergence of drug-resistant microorganisms (85) (86) (87) . Schentag and colleagues recently suggested that the use of cefazolin for presurgical prophylaxis promotes the emergence of MRSA, MRSE, and-indirectlyvancomycin-resistant enterococci (88) . These authors point out that the activity of cefazolin after a single 1g dose, expressed as the ratio of the area under the (time to serum concentration) curve to the minimum inhibitory concentration, is marginal against S. aureus, thereby selecting out the rare methicillin-resistant cells residing in the nares of persons colonized with predominantly methicillin-sensitive bacteria. Such persons are then predisposed to nosocomial infections due to MRSA, the treatment of which promotes the emergence of vancomycin-resistant enterococci.
One might posit, then, that the wider use of vancomycin would reduce the occurrence of MRSA and vancomycin-resistant enterococci infection. Zanetti et al recently used a decision-analysis model to conclude that vancomycin results in fewer infections and deaths, and lower costs compared with cefazolin (89) . Moreover, Spelman et al observed that replacing cefazolin with the combination of vancomycin and rifampicin as prophylaxis for coronary bypass graft surgery was accompanied by a decrease from 10.5% to 4.9% in the incidence of surgical-site infections at their institution (90) . Should the indications for vancomycin expand, however, we would again suggest that therapy be kept as brief as possible.
Are there alternatives to vancomycin for patients who are undergoing prosthetic valve surgery and for institutions with a high prevalence of MRSA and MRSE infections? Alternatives to vancomycin for therapy of MRSA and MRSE infections are clearly needed. European investigators suggest that teicoplanin may be superior to vancomycin for surgical prophylaxis because of its longer serum half-life and larger volume of distribution (91, 92) . The possibility that either quinupristin-dalfopristin or linezolid might be effective for prophylaxis remains to be established (4,5). What role should cardiologists and cardiac surgeons play to reduce the further spread of vancomycin-resistant bacteria? As major stakeholders in the prevention of staphylococcal infections, cardiologists and cardiac surgeons should assume leadership roles in ensuring the appropriate use of vancomycin and other agents in their institutions. Cardiology training programs should pay renewed attention to issues and methods that pertain to antibiotic management and infection control.
Conclusion
Our review of the literature reveals that the strongest evidence in support of the prophylactic use of vancomycin rather than cephalosporins is during cardiac surgeries, with particular attention to valvular surgeries in institutions with a high prevalence of MRSA and MRSE as determined by the institution's infection control department. When vancomycin is used prior to open heart surgery, the dose should be 15 mg/kg rather than a standard 1-g dose commonly recommended. In institutions with a high incidence of MRSA and MRSE, vancomycin may be used for antibiotic prophylaxis in place of cephalosporins for cardiac procedures. The routine use of vancomycin as the first-line agent in place of cephalosporins for antibiotic prophylaxis prior to cardiac surgery is still controversial.
